Abstract
Depressive disorder is a very frequent and heterogeneous syndrome. Structural imaging techniques offer a useful tool in the comprehension of neurobiological alterations that concern depressive disorder. Altered brain structures in depressive disorder have been particularly located in the prefrontal cortex (medial prefrontal cortex and orbitofrontal cortex, OFC) and medial temporal cortex areas (hippocampus). These brain areas belong to a structural and functional network related to cognitive and emotional processes putatively implicated in depressive symptoms. These volumetric alterations may also represent biological predictors of response to pharmacological treatment. In this context, major findings of magnetic resonance (MR) imaging, in relation to treatment response in depressive disorder, will here be presented and discussed.
Keywords: amitriptyline, amygdala, cingulate, citalopram, doxepine, fluoxetine, fluxovamine, hippocampus, mirtazapine, paroxetine, prefrontal cortex, reboxetine, sertraline, trimipramine, venlafaxine.
Graphical Abstract
Current Neuropharmacology
Title:Brain Structural Effects of Antidepressant Treatment in Major Depression
Volume: 13 Issue: 4
Author(s): Nicola Dusi, Stefano Barlati, Antonio Vita and Paolo Brambilla
Affiliation:
Keywords: amitriptyline, amygdala, cingulate, citalopram, doxepine, fluoxetine, fluxovamine, hippocampus, mirtazapine, paroxetine, prefrontal cortex, reboxetine, sertraline, trimipramine, venlafaxine.
Abstract: Depressive disorder is a very frequent and heterogeneous syndrome. Structural imaging techniques offer a useful tool in the comprehension of neurobiological alterations that concern depressive disorder. Altered brain structures in depressive disorder have been particularly located in the prefrontal cortex (medial prefrontal cortex and orbitofrontal cortex, OFC) and medial temporal cortex areas (hippocampus). These brain areas belong to a structural and functional network related to cognitive and emotional processes putatively implicated in depressive symptoms. These volumetric alterations may also represent biological predictors of response to pharmacological treatment. In this context, major findings of magnetic resonance (MR) imaging, in relation to treatment response in depressive disorder, will here be presented and discussed.
Export Options
About this article
Cite this article as:
Dusi Nicola, Barlati Stefano, Vita Antonio and Brambilla Paolo, Brain Structural Effects of Antidepressant Treatment in Major Depression, Current Neuropharmacology 2015; 13 (4) . https://dx.doi.org/10.2174/1570159X1304150831121909
DOI https://dx.doi.org/10.2174/1570159X1304150831121909 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Mitochondrial Diseases in Childhood
Current Molecular Medicine HIV-Infected Patients and Liver Transplantation: Who, When and Why
Current HIV Research Advances in the Immune Pathogenesis and Treatment of Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Small Ruminant Lentiviruses and Human Immunodeficiency Virus: Cousins that Take a Long View
Current HIV Research Studies on Chloride Channels and their Modulators
Current Topics in Medicinal Chemistry Delayed Multiple Non-ischemic Cerebral Enhanced Lesions After Endovascular Therapy For Left Internal Carotid Aneurysm: A Case Report
Current Medical Imaging Anti-HIV Drug Distribution to the Central Nervous System
Current Pharmaceutical Design Interplay between Catalysts and Substrates for Activity of Class Ib Aminoacyl-tRNA Synthetases and Implications for Pharmacology
Current Topics in Medicinal Chemistry Promising Pharmacological, Molecular and Cellular Treatments of Autoimmune Hepatitis
Current Pharmaceutical Design Tryptamine Induces Axonopathy and Mitochondriopathy Mimicking Neurodegenerative Diseases via Tryptophanyl-tRNA Deficiency
Current Alzheimer Research Update on the Use of Biologics in Vasculitides
Current Pharmaceutical Biotechnology From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design Cognitive, Psychological and Psychiatric Effects of Ionizing Radiation Exposure
Current Medicinal Chemistry The Cytokine Network in HIV Infection
Current Molecular Medicine The Genetics of Small-Vessel Disease
Current Medicinal Chemistry T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Rheumatoid Arthritis: An Evolutionary Force in Biologics
Current Pharmaceutical Design Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems
Current Drug Targets